Naujienos, aktualijos, renginiai
March 02, 2020 06:30 AM Eastern Standard Time OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM … Skaityti toliau
− Company further sharpens focus on patient access to innovative medicines in Latin America − Transaction further accelerates deleveraging March 02, 2020 06:00 AM Eastern Standard Time OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to … Skaityti toliau
Strengthens alignment of Growth & Emerging Markets Business Unit portfolio with Takeda’s global business areas November 05, 2019 02:00 AM Eastern Standard Time OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG (“STADA”), an international pharmaceutical … Skaityti toliau
Transaction accelerates deleveraging Agreement simplifies portfolio in Takeda’s NEMEA region OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa (NEMEA) countries within its Growth and … Skaityti toliau
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments. “The completion of this transaction marks an important step in executing Takeda’s strategy, … Skaityti toliau
Agrees to Sell Xiidra® to Novartis for up to $5.3 billion Company to Also Divest TachoSil® to Ethicon* for approximately $400 million OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”) to Novartis and its TachoSil®Fibrin Sealant Patch (“TachoSil®”) to Ethicon … Skaityti toliau